原发性胆汁性胆管炎预后的影响因素

徐黎; 郑玥琪; 时桢; 陈逸云; 邵慧江; 陈建杰

doi:10.3969/j.issn.1001-5256.2019.08.050

原发性胆汁性胆管炎预后的影响因素

DOI: 10.3969/j.issn.1001-5256.2019.08.050

上海中医药大学附属曙光医院

基金项目:

国家中医药管理局重点学科(中医传染病学科)(2010)；陈建杰上海市明中医工作室(ZYSNXD-CC-MZY003)；

详细信息

中图分类号: R575.7
计量
- 文章访问数: 1527
- HTML全文浏览量: 54
- PDF下载量: 265
- 被引次数: 0
出版历程
- 收稿日期: 2019-01-25
- 出版日期: 2019-08-20

Influencing factors for the prognosis of primary biliary cholangitis

Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine

Research funding:

摘要

摘要: 原发性胆汁性胆管炎(PBC)属于慢性胆汁淤积性自身免疫性肝病,若不予及时有效治疗可进展至肝纤维化、肝硬化,甚至终末期肝病。PBC治疗主要目的是预防终末期肝病的发生,并改善相关临床症状,提升患者生活质量。及时准确地风险分层可使难治性PBC患者受益。准确评估PBC患者的预后对于临床治疗至关重要。从宿主因素、实验室检查、药物治疗等方面综述近十年PBC预后因素的研究进展。
- 原发性胆汁性胆管炎 /
- 预后 /
- 影响因素分析
Abstract: Primary biliary cholangitis (PBC) is a chronic cholestatic autoimmune disease and may progress to liver fibrosis, liver cirrhosis, and even end-stage liver disease without timely and effective treatment. The main purpose of PBC treatment is to prevent the development of end-stage liver disease and improve related clinical symptoms and quality of life. Timely and accurate risk stratification may bring benefits to patients with refractory PBC, and an accurate evaluation of the prognosis of PBC patients is of vial importance for clinical treatment. This article reviews the research advances in the prognostic factors for PBC from the aspects of host factors, laboratory examination, and pharmacotherapy.
- primary biliary cholangitis /
- prognosis /
- root cause analysis

HTML全文

参考文献(44)

[1] BEUERS U, GERSHWIN ME, GISH RG, et al. Changing nomenclature for PBC:From ‘cirrhosis’to ‘cholangitis’[J].Dig Liver Dis, 2015, 47 (11) :924-926.

[2] LI QQ, ZHOU XM, QI XS, et al. Recommendations for the British Society of Gastroenterology/UK-PBC primary biliary cholangitis treatment and management guidelines (2018) [J]. J Clin Hepatol, 2018, 34 (6) :1191-1192. (in Chinese) 李谦谦, 周新苗, 祁兴顺, 等.《2018年英国胃肠病学会/英国PBC协作组原发性胆汁性胆管炎治疗及管理指南》推荐意见[J].临床肝胆病杂志, 2018, 34 (6) :1191-1192.

[3] YOUNOSSI ZM, BERNSTEIN D, SHIFFMAN ML, et al. Diagnosis and management of primary biliary cholangitis[J]. Am J Gastroenterol, 2019, 114 (1) :48-63.

[4] CARBONE M, MELLS GF, PELLS G, et al. Sex and age are determinants of the clinical phenotype of primary biliary cirrhosis and response to ursodeoxycholic acid[J]. Gastroenterology, 2013, 144 (3) :560-569. e7; quize13-14.

[5] CHEN S, DUAN W, LI M, et al. Prognosis of 732 ursodeoxycholic acid-treated patients with primary biliary cholangitis:A single center follow-up study from China[J]. J Gastroenterol Hepatol, 2018.[Epub ahead of print]

[6] EASL clinical practice guidelines:The diagnosis and management of patients with primary biliary cholangitis[J]. J Hepatol, 2017, 67 (1) :145-172.

[7] QUARNETI C, MURATORI P, LALANNE C, et al. Fatigue and pruritus at onset identify a more aggressive subset of primary biliary cirrhosis[J]. Liver Int, 2015, 35 (2) :636-641.

[8] LINDOR KD, GERSHWIN ME, POUPON R, et al. Primary biliary cirrhosis[J]. Hepatology, 2009, 50 (1) :291-308.

[9] API AM, BELSITO D, BOTELHO D, et al. RIFM fragrance ingredient safety assessment, 1-oxaspiro[4. 5]decan-2-one, 8-ethyl-, trans-, CAS Registry Number 91069-40-8[J]. Food Chem Toxicol, 2018, 122 (Suppl 1) :s633-s640.

[10] KOUROUMALIS E, SAMONAKIS D, VOUMVOURAKI A. Biomarkers for primary biliary cholangitis:Current perspectives[J]. Hepat Med, 2018, 10:43-53.

[11] VLEGGAAR FP, van BUUREN HR. No prognostic significance of antimitochondrial antibody profile testing in primary biliary cirrhosis[J]. Hepatogastroenterology, 2004, 51 (58) :937-940.

[12] RIGOPOULOU EI, DAVIES ET, BOGDANOS DP, et al. Antimitochondrial antibodies of immunoglobulin G3 subclass are associated with a more severe disease course in primary biliary cirrhosis[J]. Liver Int, 2007, 27 (9) :1226-1231.

[13] WESIERSKA-GADEK J, PENNER E, BATTEZZATI PM, et al.Correlation of initial autoantibody profile and clinical outcome in primary biliary cirrhosis[J]. Hepatology, 2006, 43 (5) :1135-1144.

[14] NAKAMURA M, KONDO H, MORI T, et al. Anti-gp210 and anti-centromere antibodies are different risk factors for the progression of primary biliary cirrhosis[J]. Hepatology, 2007, 45 (1) :118-127.

[15] MIYACHI K, HANKINS RW, MATSUSHIMA H, et al. Profile and clinical significance of anti-nuclear envelope antibodies found in patients with primary biliary cirrhosis:A multicenter study[J]. J Autoimmun, 2003, 20 (3) :247-254.

[16] TANA MM, SHUMS Z, MILO J, et al. The significance of autoantibody changes over time in primary biliary cirrhosis[J].Am J Clin Pathol, 2015, 144 (4) :601-606.

[17] JOSHITA S, UMEMURA T, USAMI Y, et al. Serum autotaxin is a useful disease progression marker in patients with primary biliary cholangitis[J]. Sci Rep, 2018, 8 (1) :8159.

[18] JOSHITA S, ICHIKAWA Y, UMEMURA T, et al. Serum autotaxin is a useful liver fibrosis marker in patients with chronic hepatitis B virus infection[J]. Hepatol Res, 2018, 48 (4) :275-285.

[19] HAYASHI M, ABE K, FUJITA M, et al. Changes in serum levels of leucine-richα2-glycoprotein predict prognosis in primary biliary cholangitis[J]. Hepatol Res, 2018.[Epub ahead of print]

[20] AIBA Y, HARADA K, ITO M, et al. Increased expression and altered localization of cathepsin Z are associated with progression to jaundice stage in primary biliary cholangitis[J]. Sci Rep, 2018, 8 (1) :11808.

[21] UMEMURA T, JOSHITA S, SEKIGUCHI T, et al. Serum wisteria floribunda agglutinin-positive mac-2-binding protein level predicts liver fibrosis and prognosis in primary biliary cirrhosis[J]. Am J Gastroenterol, 2015, 110 (6) :857-864.

[22] LAMMERS WJ, HIRSCHFIELD GM, CORPECHOT C, et al.Development and validation of a scoring system to predict outcomes of patients with primary biliary cirrhosis receiving ursodeoxycholic acid therapy[J]. Gastroenterology, 2015, 149 (7) :1804-1812. e4.

[23] XING G, PAN L, YI C, et al. Design, synthesis and biological evaluation of 5- (2-amino-1-hydroxyethyl) -8-hydroxyquinolin-2 (1H) -one derivatives as potentβ2-adrenoceptor agonists[J]. Bioorg Med Chem, 2018.[Epub ahead of print]

[24] HAGA Y, KANDA T, SASAKI R, et al. Serum wisteria floribunda agglutinin-positive mac-2 binding protein could not always predict early cirrhosis in non-viral liver diseases[J].Diseases, 2016, 4 (4) :38.

[25] HUANG YL, YAO DK, HU ZD, et al. Value of baseline platelet count for prediction of complications in primary biliary cirrhosis patients treated with ursodeoxycholic acid[J]. Scand J Clin Lab Invest, 2013, 73 (1) :17-23.

[26] LIN L, PIAO M, JIANG X, et al. Does neutrophil-to-lymphocyte ratio predict 1-year mortality in patients with primary biliary cholangitis? Results from a retrospective study with validation cohort[J]. BMJ Open, 2017, 7 (7) :e015304.

[27] CHEUNG KS, SETO WK, FUNG J, et al. Prediction of hepatocellular carcinoma development by aminotransferase to platelet ratio index in primary biliary cholangitis[J]. World J Gastroenterol, 2017, 23 (44) :7863-7874.

[28] ALMPANIS Z, DEMONAKOU M, TINIAKOS D. Evaluation of liver fibrosis:“Something old, something new…”[J]. Ann Gastroenterol, 2016, 29 (4) :445-453.

[29] SHI TY, ZHANG LN, CHEN H, et al. Risk factors for hepatic decompensation in patients with primary biliary cirrhosis[J].World J Gastroenterol, 2013, 19 (7) :1111-1118.

[30] HUANG YQ. Recent advances in the diagnosis and treatment of primary biliary cholangitis[J]. World J Hepatol, 2016, 8 (33) :1419-1441.

[31] FLOREANI A, CAROLI D, VARIOLA A, et al. A 35-year fol owup of a large cohort of patients with primary biliary cirrhosis seen at a single centre[J]. Liver Int, 2011, 31 (3) :361-368.

[32] MOMAH N, LINDOR KD. Primary biliary cirrhosis in adults[J].Expert Rev Gastroenterol Hepatol, 2014, 8 (4) :427-433.

[33] SHI J, WU C, LIN Y, et al. Long-term effects of mid-dose ursodeoxycholic acid in primary biliary cirrhosis:A metaanalysis of randomized controlled trials[J]. Am J Gastroenterol, 2006, 101 (7) :1529-1538.

[34] TER BPC, SCHALM SW, HANSEN BE, et al. Prognosis of ursodeoxycholic Acid-treated patients with primary biliary cirrhosis. Results of a 10-yr cohort study involving 297 patients[J]. Am J Gastroenterol, 2006, 101 (9) :2044-2050.

[35] BAHAR R, WONG KA, LIU CH, et al. Update on new drugs and those in development for the treatment of primary biliary cholangitis[J]. Gastroenterol Hepatol (N Y) , 2018, 14 (3) :154-163.

[36] CARBONE M, SHARP SJ, FLACK S, et al. The UK-PBC risk scores:Derivation and validation of a scoring system for longterm prediction of end-stage liver disease in primary biliary cholangitis[J]. Hepatology, 2016, 63 (3) :930-950.

[37] ANGULO P, LINDOR KD, THERNEAU TM, et al. Utilization of the Mayo risk score in patients with primary biliary cirrhosis receiving ursodeoxycholic acid[J]. Liver, 1999, 19 (2) :115-121.

[38] PARS A, CABALLERA L, RODS J. Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic Acid[J]. Gastroenterology, 2006, 130 (3) :715-720.

[39] CORPECHOT C, ABENAVOLI L, RABAHI N, et al. Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis[J]. Hepatology, 2008, 48 (3) :871-877.

[40] KUIPER EM, HANSEN BE, de VRIES RA, et al. Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid[J]. Gastroenterology, 2009, 136 (4) :1281-1287.

[41] KUMAGI T, GUINDI M, FISCHER SE, et al. Baseline ductopenia and treatment response predict long-term histological progression in primary biliary cirrhosis[J]. Am J Gastroenterol, 2010, 105 (10) :2186-2194.

[42] CORPECHOT C, CHAZOUILLRES O, POUPON R. Early primary biliary cirrhosis:Biochemical response to treatment and prediction of long-term outcome[J]. J Hepatol, 2011, 55 (6) :1361-1367.

[43] AZEMOTO N, ABE M, MURATA Y, et al. Early biochemical response to ursodeoxycholic acid predicts symptom development in patients with asymptomatic primary biliary cirrhosis[J]. J Gastroenterol, 2009, 44 (6) :630-634.

[44] YANG F, YANG Y, WANG Q, et al. The risk predictive values of UK-PBC and GLOBE scoring system in Chinese patients with primary biliary cholangitis:The additional effect of anti-gp210[J]. Aliment Pharmacol Ther, 2017, 45 (5) :733-743.

施引文献

资源附件(0)

访问统计